Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (213)	4/6/2002 7:34:28 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 897

Of those, short the one with the fatest market cap. But if that is emis, you are looking near into the maw of P3 results in oral POH (plain old heparin) and/or a marketing deal for oral insulin. But some people say POH even if delivered orally is still too unpredictable to make inroads against lmwh. In either case, emis probably has too much near term enterprise upside risk to short for any purpose other than knowing oral-POH won't work.